Spots Global Cancer Trial Database for nasopharyngeal carcinoma
Every month we try and update this database with for nasopharyngeal carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal Carcinoma | NCT03321539 | Nasopharyngeal ... | CCRT+GP CCRT+PF | 18 Years - 65 Years | Sun Yat-sen University | |
| GNT Induction Treatment in Locally Advanced NPC | NCT06026878 | Nasopharyngeal ... | gemcitabine,nim... gemcitabine, ci... | 18 Years - 75 Years | Air Force Military Medical University, China | |
| 18F-FMISO PET Guided Dose Escalation in Nasopharyngeal Carcinoma - a Feasibility and Planning Study | NCT04995185 | Nasopharyngeal ... | (18)F-fluoromis... | 21 Years - 99 Years | National Cancer Centre, Singapore | |
| By Comparing TPF Induction Chemotherapy Combined With Nimotuzumab Concurrent Radiotherapy and Cisplatin Concurrent Radio-chemotherapy for Locally Advanced NPC | NCT03557112 | Nasopharyngeal ... | Nimotuzumab Cisplatin | 18 Years - 70 Years | Guiyang Medical University | |
| Chemoradiotherapy for Patients With Locally Advanced Nasopharyngeal Carcinoma Using Raltitrexed-Cisplatin | NCT02562599 | Nasopharyngeal ... | raltitrexed-cis... Intensity-modul... | 18 Years - 70 Years | Hubei Cancer Hospital | |
| Long-term Treatment Outcome for Stage III NPC Patients and Risk Grouping by Plasma EBV DNA | NCT03314051 | Nasopharyngeal ... EBV Related Car... | 20 Years - 80 Years | Taichung Veterans General Hospital | ||
| The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC | NCT06182657 | Nasopharyngeal ... Pathologic Comp... Tumor Microenvi... | 18 Years - | Jiangxi Provincial Cancer Hospital | ||
| Endoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma Patients | NCT03353467 | Nasopharyngeal ... Endoscopic Surg... Primary Naphary... Stage I Nasopha... | Endoscopic surg... Intensity-modul... | 18 Years - 70 Years | Sun Yat-sen University | |
| Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma | NCT04437329 | Nasopharyngeal ... | Docetaxel, neda... Docetaxel, cisp... Nedaplatin Cisplatin Intensity modul... | 18 Years - 65 Years | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | |
| Benefit of Adding Chemotherapy And/Or Modification of Radiotherapy Schedule for Advance Nasopharyngeal Carcinoma (T3-4N0-1M0) | NCT00563862 | Nasopharyngeal ... Carcinoma, Squa... | Conventional RT Accelerated RT Cisplatin 5-fluorouracil | - 70 Years | Hospital Authority, Hong Kong | |
| Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma | NCT02801487 | Nasopharyngeal ... | Carbon ion radi... Cisplatin | 18 Years - 70 Years | Shanghai Proton and Heavy Ion Center | |
| Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma | NCT01540136 | Nasopharyngeal ... | Nedaplatin Cisplatin | 18 Years - 65 Years | Sun Yat-sen University | |
| Verification of Harmonization of Plasma Epstein-Barr Virus DNA Measurements | NCT05037357 | Nasopharyngeal ... | Plasma EBV DNA ... | 18 Years - 70 Years | Sun Yat-sen University | |
| Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC | NCT04833257 | Nasopharyngeal ... | GP combine with... | 18 Years - 70 Years | Sun Yat-sen University | |
| Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma | NCT03984357 | Nasopharyngeal ... | PD-1 blocking a... Gemcitabine Cisplatin Intensity-modul... | 18 Years - 65 Years | Sun Yat-sen University | |
| Effect of Edaravone on Radiation-induced Temporal Lobe Necrosis | NCT01865201 | Nasopharyngeal ... Brain Necrosis | Edaravone Common fundamen... | 18 Years - | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma | NCT04437329 | Nasopharyngeal ... | Docetaxel, neda... Docetaxel, cisp... Nedaplatin Cisplatin Intensity modul... | 18 Years - 65 Years | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | |
| Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma | NCT02269943 | Nasopharyngeal ... | CC-486 | 18 Years - | Celgene | |
| Effect of Hepatectomy on the Prognosis of Patients With Nasopharyngeal Carcinoma Liver Metastases | NCT05771025 | Nasopharyngeal ... Liver Metastase... | Hepatectomy | 18 Years - 70 Years | Fudan University | |
| Hepatic Artery Infusion Pump for NPC Liver Metastases | NCT03876574 | Nasopharyngeal ... Neoplasm Metast... Liver | DSA-guided impl... Gemcitabine Floxuridine dexamethasone | - | Xiangya Hospital of Central South University | |
| The Value of Diagnosis and Outcome Prediction in CTC for Metastatic NPC Patients | NCT02505139 | Nasopharyngeal ... | the number of c... | 18 Years - 65 Years | Sun Yat-sen University | |
| The Effect of COX-2 Inhibitor on Radiosensitivity in Nasopharyngeal Carcinoma | NCT02537925 | Nasopharyngeal ... | Celecoxib Nedaplatin Concurrent Radi... | 18 Years - 60 Years | Nanning Second People's Hospital | |
| Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma | NCT03919552 | Cisplatin Carboplatin NPC | Docetaxel,Carbo... Docetaxel,Cispl... Carboplatin-bas... Cisplatin-based... | 18 Years - 64 Years | Nanfang Hospital, Southern Medical University | |
| Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC | NCT04833257 | Nasopharyngeal ... | GP combine with... | 18 Years - 70 Years | Sun Yat-sen University | |
| A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors | NCT03517488 | Melanoma Breast Carcinom... Hepatocellular ... Urothelial Carc... Squamous Cell C... Renal Cell Carc... Colorectal Carc... Non-small Cell ... Gastric or Gast... Endometrial Car... Mesothelioma Neuroendocrine ... Cervical Cancer Small Cell Lung... Squamous Cell C... Castration-Resi... Nasopharyngeal ... Cholangiocarcin... Basal Cell Carc... Ovarian Carcino... Fallopian Tube ... Thymoma Thymic Carcinom... Squamous Cell C... Vulvar Carcinom... Solid Tumors Wi... Malignant Adnex... Non-squamous Ce... | XmAb20717 | 18 Years - | Xencor, Inc. | |
| Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma | NCT03984357 | Nasopharyngeal ... | PD-1 blocking a... Gemcitabine Cisplatin Intensity-modul... | 18 Years - 65 Years | Sun Yat-sen University | |
| Dietary Nitrate on Salivary Flow for Nasopharyngeal Carcinoma Patients | NCT02854410 | Nasopharyngeal ... | Sodium nitrate sodium chloride | 20 Years - 70 Years | Capital Medical University | |
| Late Sequelae of Childhood and Adolescent Nasopharyngeal Carcinoma Survivors After Radiotherapy | NCT03398980 | Nasopharyngeal ... | survivors treat... | 7 Years - 18 Years | Sun Yat-sen University | |
| Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma (NPC) | NCT00817583 | Nasopharyngeal ... | docetaxel, cisp... 3D-CRT (three-d... | 18 Years - 70 Years | Fudan University | |
| Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma | NCT03097939 | Nasopharyngeal ... | Ipilimumab Nivolumab | 21 Years - 80 Years | National Cancer Centre, Singapore | |
| Effect of Edaravone on Radiation-induced Temporal Lobe Necrosis | NCT01865201 | Nasopharyngeal ... Brain Necrosis | Edaravone Common fundamen... | 18 Years - | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma | NCT04778956 | Nasopharyngeal ... PD-1 Surgery | Toripalimab salvage surgery | 18 Years - 70 Years | Sun Yat-sen University | |
| Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma | NCT05201859 | Nasopharyngeal ... | Sintilimab Capecitabine | 18 Years - 70 Years | Sun Yat-sen University | |
| A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma | NCT06118333 | Nasopharyngeal ... | BL-B01D1 capecitabine gemcitabine docetaxel | 18 Years - | Sichuan Baili Pharmaceutical Co., Ltd. | |
| Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma | NCT04548271 | Nasopharyngeal ... | Camrelizumab Apatinib | 18 Years - 75 Years | Sun Yat-sen University | |
| A Two-blinded, Multicentre, Phase II/III RCT of Concurrent Chemo-radiotherapy Combined or Not Combined With TNF as the Therapy for LA-NPC | NCT05433597 | Nasopharyngeal ... TNF Chemo-radiother... | 5-fu Cisplatin Radiotherapy TNF Placebo | 18 Years - 60 Years | Sun Yat-sen University | |
| A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839 | NCT00212108 | Nasopharyngeal ... | celecoxib, gefi... | 18 Years - | National University Hospital, Singapore | |
| Serial Plasma EBV DNA for Nasopharyngeal Carcinoma | NCT02476669 | Nasopharyngeal ... | - | The University of Hong Kong | ||
| EUS-FNA for Retropharyngeal Lymph Node (RPLN) in Recurrent Nasopharyngeal Carcinoma (NPC) Patients | NCT03006588 | Nasopharyngeal ... | EUS-FNA for RPL... | 18 Years - 75 Years | Sun Yat-sen University | |
| Iron Isomaltide for Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal Carcinoma | NCT05913414 | Nasopharyngeal ... Iron-deficiency Anemia | Iron Isomaltosi... Polysaccharide ... Intensity-modul... | 18 Years - 65 Years | Sun Yat-sen University | |
| Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma | NCT04004871 | Nasopharyngeal ... Nasopharyngeal ... Nasopharynx Can... | Nab-paclitaxel,... concurrent chem... | 18 Years - 60 Years | Guangxi Medical University | |
| Reducing High Risk Primary Tumor Clinical Target Volumes (CTVp1) in Non-metastatic Nasopharyngeal Carcinoma | NCT05994170 | Nasopharyngeal ... Intensity-Modul... | Reduction CTVp1 Non-reduction C... | 18 Years - 70 Years | Zhongshan People's Hospital, Guangdong, China | |
| Development of a Machine Learning Model for Nasopharyngeal Carcinoma Screening Based on Tongue Imaging | NCT06129201 | Nasopharyngeal ... | Tongue image | 18 Years - 80 Years | Fifth Affiliated Hospital, Sun Yat-Sen University | |
| A Retrospective Study Reveals the Relationship Between gp42-IgG Epitopes and EBV-associated NPC | NCT05949749 | Nasopharyngeal ... | Epitope explora... | - | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma | NCT00834093 | Nasopharyngeal ... | Epstein-Barr Vi... | 18 Years - | Dana-Farber Cancer Institute | |
| A Multicenter Randomized Controlled Clinical Study on the Treatment of T3N1M0 High Risk Nasopharyngeal Carcinoma With or Without Induction Chemotherapy Before Concurrent Radiotherapy and Chemotherapy | NCT05622474 | Nasopharyngeal ... | Induction chemo... Concurrent chem... IMRT | 18 Years - 70 Years | Sun Yat-sen University | |
| OPB-51602 in Locally Advanced Nasopharyngeal Carcinoma Prior to Definitive Chemoradiotherapy | NCT02058017 | Nasopharyngeal ... | OPB-51602 | 21 Years - | National University Hospital, Singapore | |
| Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) | NCT03682055 | Nasopharyngeal ... Nasopharyngeal ... | VK-2019 | 18 Years - | Cullinan Therapeutics Inc. | |
| Prospective Comparisons of Clinical Trial and Real-world Outcomes in Nasopharyngeal Carcinoma | NCT04108338 | Nasopharyngeal ... | Trial setting | 8 Years - 79 Years | Sun Yat-sen University | |
| CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC | NCT05724355 | Nasopharyngeal ... | Dalpiciclib Ise... | 18 Years - 70 Years | Sun Yat-sen University | |
| Reducing Target Volumes in NPC Treated With Induction Chemotherapy Followed by Concurrent Chemoradiotherapy | NCT04384627 | Nasopharyngeal ... Induction Chemo... Radiotherapy | Delineating the... | 18 Years - 70 Years | Sun Yat-sen University | |
| A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma | NCT04736810 | Nasopharyngeal ... | AK105 Cisplatin Gemcitabine Anlotinib hydro... | 18 Years - 75 Years | Akeso | |
| Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy | NCT05892354 | Locally Advance... | Enteral immunon... Standard entera... | 18 Years - 70 Years | First Affiliated Hospital of Guangxi Medical University | |
| Induction Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | NCT01245959 | Nasopharyngeal ... | Docetaxel, cisp... Concurrent chem... | 18 Years - 59 Years | Sun Yat-sen University | |
| The Value of Concurrent Chemoradiotherapy for Stage II Nasopharyngeal Carcinoma | NCT01187238 | Nasopharyngeal ... | cisplatin | 18 Years - 70 Years | ChineseAMS | |
| Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Nasopharyngeal Carcinoma | NCT02360501 | Nasopharyngeal ... | Docetaxel Cisplatin Capecitabine | 18 Years - 75 Years | Sun Yat-sen University | |
| Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma | NCT04350190 | Nasopharyngeal ... | Apatinib mesyla... PD-1 | 18 Years - 70 Years | Guilin Medical University, China | |
| Pretreatment With HCQ Before Radiotherapy and Chemotherapy in Advanced NPC Patients | NCT06389201 | Nasopharyngeal ... | HCQ Placebo | 20 Years - 70 Years | Affiliated Hospital of Nantong University | |
| The Value of Concurrent Chemoradiotherapy for Stage II Nasopharyngeal Carcinoma | NCT01187238 | Nasopharyngeal ... | cisplatin | 18 Years - 70 Years | ChineseAMS | |
| Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT | NCT04215510 | Recurrent Nasop... | endonasal endos... radiation thera... | 18 Years - 70 Years | Eye & ENT Hospital of Fudan University | |
| Effect of Bevacizumab on Radiation-induced Brain Necrosis in Patients With Nasopharyngeal Carcinoma | NCT01621880 | Nasopharyngeal ... Adverse Effect ... Brain Necrosis | bevacizumab Corticosteroid | 18 Years - | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Sequencing-based Counting of Plasma Epstein-Barr Virus DNA in Non-metastatic Nasopharyngeal Carcinoma | NCT06321939 | Nasopharyngeal ... Herpesvirus 4, ... | EBV-DNA next ge... | 18 Years - | Hunan Cancer Hospital | |
| Nasopharyngeal Carcinoma Post IMRT | NCT02597426 | Nasopharyngeal ... | 18 Years - | University Health Network, Toronto | ||
| The Value of Diagnosis and Outcome Prediction in CTC for Metastatic NPC Patients | NCT02505139 | Nasopharyngeal ... | the number of c... | 18 Years - 65 Years | Sun Yat-sen University | |
| Clincal Study of Reduced Target Radiotherapy in Nasopharyngeal Carcinoma | NCT05741008 | Toxicity Due to... Nasopharyngeal ... | Target range | 18 Years - 65 Years | First Affiliated Hospital of Kunming Medical University | |
| Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) | NCT03769467 | Nasopharyngeal ... Nasopharyngeal ... Epstein-Barr Vi... Epstein-Barr Vi... Epstein-Barr Vi... | tabelecleucel pembrolizumab | 12 Years - | Atara Biotherapeutics | |
| Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy | NCT00700440 | Nasopharyngeal ... | C225 (cetuximab... | 18 Years - 69 Years | Sun Yat-sen University | |
| Sequencing-based Counting of Plasma Epstein-Barr Virus DNA in Non-metastatic Nasopharyngeal Carcinoma | NCT06321939 | Nasopharyngeal ... Herpesvirus 4, ... | EBV-DNA next ge... | 18 Years - | Hunan Cancer Hospital | |
| Individualized Elective Neck Irradiation Based on MRI in NPC Patients | NCT02642107 | Nasopharyngeal ... | Elective neck i... Whole neck irra... | 18 Years - 65 Years | Sun Yat-sen University | |
| Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer | NCT04825990 | Nasopharyngeal ... | Pembrolizumab | 18 Years - | Gruppo Oncologico del Nord-Ovest | |
| HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Nasopharyngeal Carcinoma | NCT02523430 | Nasopharyngeal ... | interventional ... | 18 Years - 80 Years | Fuda Cancer Hospital, Guangzhou | |
| Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy for Nasopharyngeal Carcinoma | NCT04447326 | Nasopharyngeal ... | Toripalimab, En... IC＋CCRT | 18 Years - 65 Years | First Affiliated Hospital of Guangxi Medical University | |
| Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC) | NCT03267498 | Nasopharyngeal ... | Nivolumab Cisplatin Radiation Thera... | 18 Years - | University of California, San Francisco | |
| Effect of Edaravone on Radiation-induced Temporal Lobe Necrosis | NCT01865201 | Nasopharyngeal ... Brain Necrosis | Edaravone Common fundamen... | 18 Years - | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Phase III: Assess Conventional RT w/ Conventional Plus Accelerated Boost RT in the Treatment of Nasopharyngeal CA | NCT00535795 | Nasopharyngeal ... | Radiation Thera... | - | King Faisal Specialist Hospital & Research Center | |
| Immune Score Based Radiomics in Nasopharyngeal Carcinoma | NCT05126160 | Nasopharyngeal ... | Immune Score Ba... | 18 Years - 70 Years | Zhejiang Cancer Hospital | |
| EPstein-barr Virus DNA Response to Systemic Therapy for Treatment Adaptation in High Risk NPC (EP-STAR) | NCT04072107 | Nasopharyngeal ... | sintilimab Capecitabine | 18 Years - 65 Years | Sun Yat-sen University | |
| Foscan®-Mediated Photodynamic Therapy Versus Brachytherapy in Patients With Nasopharyngeal Carcinoma | NCT01086488 | Nasopharyngeal ... | FOSCAN | 18 Years - 69 Years | Ministry of Health, Malaysia | |
| Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy | NCT03390738 | Nasopharyngeal ... | Nivolumab | 18 Years - | The University of Hong Kong | |
| Development of a Machine Learning Model for Nasopharyngeal Carcinoma Screening Based on Tongue Imaging | NCT06129201 | Nasopharyngeal ... | Tongue image | 18 Years - 80 Years | Fifth Affiliated Hospital, Sun Yat-Sen University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
